Endobronchial photodynamic therapy for lung cancer

  title={Endobronchial photodynamic therapy for lung cancer},
  author={Gregory Loewen and Ravindra Pandey and David A. Bellnier and Barbara H Henderson and Thomas J. Dougherty},
  journal={Lasers in Surgery and Medicine},
Endobronchial photodynamic therapy (PDT) is a minimally invasive technique for the palliation of major airway obstruction from lung cancer, and for the treatment of endobronchial microinvasive lung cancer. 

Photodynamic Therapy and Its Use in Lung Disease

Application of photodynamic therapy for thoracic malignancy will likely continue to expand as emerging data suggest it is both safe and efficacious for use in the periphery with non-small cell lung cancer.

Photodynamic therapy of disseminated non‐small cell lung carcinoma in a murine model

This report aims to characterize a model for PDT of disseminated non‐small cell lung carcinoma grown orthotopically in nude mice, and to evaluate the effect of PDT on tumor and normal tissues.

Photodynamic therapy as an innovative treatment for malignant pleural mesothelioma.

  • J. Friedberg
  • Medicine
    Seminars in thoracic and cardiovascular surgery
  • 2009
Local control and survival rates have been sufficiently rewarding to merit ongoing development of this combination of surgical technique and PDT, and appears to bolster an immunologic effect by rendering the cancer cells that have been destroyed by the light-activated photosensitizer more presentable to the immune system.

Photodynamic therapy via navigational bronchoscopy for peripheral lung cancer in dogs

The use of PDT delivered by electromagnetic navigational bronchoscopy to treat peripheral lung cancer in dogs and its effects on surrounding healthy lung tissue is studied.

Photodynamic therapy (PDT) using HPPH for the treatment of precancerous lesions associated with barrett's esophagus

Toxicity and optimal drug and light dose with endoscopic HPPH‐PDT are explored and the efficacy of one time treatment with HPPH (2‐[1‐hexyloxyethyl]‐2‐devinyl pyropheophorbide‐a) is studied.

Pheophorbide a as a photosensitizer in photodynamic therapy: In vivo considerations

Pheophorbide a based photodynamic therapy induces apoptosis via mitochondrial-mediated pathway in human uterine carcinosarcoma through mitochondria-mediated pathways through cell reprograming.

Photodynamic therapy with 3‐(1′‐hexyloxyethyl) pyropheophorbide‐a for early‐stage cancer of the larynx: Phase Ib study

Results regarding the safety of 3‐(1′‐hexyloxyethyl) pyropheophorbide‐a (HPPH) mediated photodynamic therapy (PDT) in early laryngeal disease are reported and preliminary information on treatment responses is offered.

Interventional pulmonology approaches in the diagnosis and treatment of early stage non small cell lung cancer.

Interventional pulmonology is an evolving field that utilizes minimally invasive modalities for the initial diagnosis and staging of suspected lung cancers and can also offer palliation for inoperable cancers and those with late stage diseases.

Adjuvant intraoperative photodynamic therapy in head and neck cancer.

The adjuvant use of HPPH-photodynamic therapy and surgery for head and neck squamous cell carcinoma seems safe and deserves further study.



Photodynamic therapy and/or external beam radiation therapy for roentgenologically occult lung cancer

Thirty‐nine roentgenologically occult lung cancers in 29 patients were treated using photodynamic therapy (PDT) and/or thoracic radiotherapy (TRT) from January 1986 to March 1992, with the exception of one mixed‐tumor case.

Photodynamic therapy. Its use in the management of bronchogenic carcinoma.

Photodynamic therapy is an investigational treatment of various types of carcinoma. It involves a photosensitizing agent which, when exposed to light of the proper wavelength, forms toxic oxygen

HpD photodynamic therapy for obstructing lung cancer.

Twenty-two patients with endobronchial cancer of the lungs have been treated with photoradiation therapy (PRT) employing a set protocol of 3.0 mg/kg hematoporphyrin derivative (HpD) administered

Photoradiation therapy of endobronchial lung cancer. Large obstructing tumors, nonobstructing tumors, and early-stage bronchial cancer lesions.

Photoradiation (photodynamic) therapy of endobronchial primary and metastatic lung cancers uniformly results in a complete response--that is, the opening up of totally or partially obstructed bronchi

Photodynamic therapy for lung cancer--a review of 19 years' experience.

  • H. Kato
  • Medicine
    Journal of photochemistry and photobiology. B, Biology
  • 1998

Photoradiation therapy of endobronchial lung cancer. Large obstructing tumors, nonobstructing tumors, and early-stage bronchial cancer lesions.

Photoradiation (photodynamic) therapy of endobronchial primary and metastatic lung cancers uniformly results in a complete response, and the trachea and main and lobar bronchi, as well as segmental and subsegmental Bronchi, can be entirely freed of tumor and completely opened up.

Photodynamic laser therapy for the treatment of early-stage bronchogenic carcinoma.

It is concluded that photodynamic therapy is effective in the treatment of superficial lung cancer in which complete remission can be expected.

Detection and localization of early lung cancer by fluorescence bronchoscopy

Fluorescence bronchoscopy is a new diagnostic tool for the detection of preinvasive bronchial lesions, which are very small and thin and difficult to localize by conventional white‐light bronchoscope.

Photodynamic therapy in the palliation of late stage obstructing non-small cell lung cancer.

Photodynamic therapy selectively destroys malignant tumors by laser activation of injected hematoporphyrin derivative. Between July 1985 and January 1989, ten patients underwent 13 courses of PDT for

High dose rate brachytherapy improves resectability in squamous cell lung cancer.

A 44-year old man with squamous cell carcinoma of the left lower lobe extending to the mucosa of the main carina, was treated with high dose rate brachytherapy prior to surgery, and remains disease-free after a follow-up period of 43 months.